STERIS (NYSE:STE) Releases FY 2025 Earnings Guidance

STERIS (NYSE:STE) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 9.050-9.150 for the period, compared to the consensus EPS estimate of 9.060. The company issued revenue guidance of $5.4 billion-$5.4 billion, compared to the consensus revenue estimate of $5.5 billion.

STERIS Trading Up 0.7 %

STERIS stock traded up $1.57 during trading hours on Wednesday, reaching $220.97. 887,926 shares of the company’s stock were exchanged, compared to its average volume of 476,648. The firm’s 50 day simple moving average is $212.26 and its 200 day simple moving average is $224.61. STERIS has a twelve month low of $197.82 and a twelve month high of $248.24. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $21.81 billion, a PE ratio of 50.45 and a beta of 0.84.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts’ consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.78% and a net margin of 8.02%. Research analysts predict that STERIS will post 9.11 earnings per share for the current year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 1.03%. The ex-dividend date is Thursday, February 20th. STERIS’s dividend payout ratio is presently 52.05%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research note on Friday, November 8th. Piper Sandler upped their price target on STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday. Stephens reissued an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research note on Thursday, November 7th. StockNews.com downgraded STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a report on Monday, November 18th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $263.75.

Insider Transactions at STERIS

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the sale, the senior vice president now owns 11,372 shares in the company, valued at approximately $2,471,363.04. This trade represents a 12.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.14% of the company’s stock.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.